CN1737004A - 康布瑞汀化合物的制备方法 - Google Patents
康布瑞汀化合物的制备方法 Download PDFInfo
- Publication number
- CN1737004A CN1737004A CN 200510057001 CN200510057001A CN1737004A CN 1737004 A CN1737004 A CN 1737004A CN 200510057001 CN200510057001 CN 200510057001 CN 200510057001 A CN200510057001 A CN 200510057001A CN 1737004 A CN1737004 A CN 1737004A
- Authority
- CN
- China
- Prior art keywords
- reaction
- ca4p
- inert solvent
- solvent
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 9
- -1 Combretastatin compound Chemical class 0.000 title description 5
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 title description 2
- 229960005537 combretastatin A-4 Drugs 0.000 claims abstract description 15
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 claims abstract description 15
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 claims abstract description 13
- 150000004713 phosphodiesters Chemical class 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 230000007062 hydrolysis Effects 0.000 claims abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 3
- 229960005527 combretastatin A-4 phosphate Drugs 0.000 claims abstract 4
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims abstract 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 230000006837 decompression Effects 0.000 claims description 15
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000012442 inert solvent Substances 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000002516 radical scavenger Substances 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005002 aryl methyl group Chemical group 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims 1
- 238000007039 two-step reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 9
- 125000003963 dichloro group Chemical group Cl* 0.000 description 6
- 150000003014 phosphoric acid esters Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DMPREIBRPICGNW-UHFFFAOYSA-N [O].C(=C)Cl Chemical compound [O].C(=C)Cl DMPREIBRPICGNW-UHFFFAOYSA-N 0.000 description 2
- CPZHJYJSCCEDQX-UHFFFAOYSA-N [O]C1=CC=C([N+]([O-])=O)C=C1 Chemical compound [O]C1=CC=C([N+]([O-])=O)C=C1 CPZHJYJSCCEDQX-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- ILUSBJDVXKZYEP-UHFFFAOYSA-N 4-(aminomethyl)oxan-4-ol;hydrochloride Chemical compound Cl.NCC1(O)CCOCC1 ILUSBJDVXKZYEP-UHFFFAOYSA-N 0.000 description 1
- 241000375691 Combretum caffrum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100570010A CN1319978C (zh) | 2005-04-06 | 2005-04-06 | 康布瑞汀化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100570010A CN1319978C (zh) | 2005-04-06 | 2005-04-06 | 康布瑞汀化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1737004A true CN1737004A (zh) | 2006-02-22 |
CN1319978C CN1319978C (zh) | 2007-06-06 |
Family
ID=36079975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100570010A Active CN1319978C (zh) | 2005-04-06 | 2005-04-06 | 康布瑞汀化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1319978C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101186620B (zh) * | 2007-10-19 | 2010-09-08 | 中国科学院广州化学研究所 | 一种含酚羟基的二苯乙烯类化合物的磷酸酯盐的制备方法 |
CN101891772A (zh) * | 2010-07-16 | 2010-11-24 | 广东肇庆星湖生物科技股份有限公司 | 一种5’-核苷酸二钠的制备方法 |
CN101220054B (zh) * | 2008-01-29 | 2011-05-25 | 成都恒基医药科技有限公司 | 康普瑞汀a-4磷酸酯二钠盐的制备方法 |
CN102731565A (zh) * | 2011-04-07 | 2012-10-17 | 复旦大学 | 一种二苯乙烯类化合物的水溶性衍生物及其制备方法和用途 |
CN106146548A (zh) * | 2015-04-17 | 2016-11-23 | 中山大学 | 一种芳氧基磷酸酯单钠盐的制备及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
DE10142881A1 (de) * | 2001-09-03 | 2003-04-03 | Jomed Gmbh | Implantate mit Combretastatin A-4 (CA4) |
DE60225477T2 (de) * | 2002-01-03 | 2009-03-26 | Invista Technologies S.A.R.L. | Garnherstellungsverfahren und -vorrichtung |
CA2486215A1 (en) * | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CN100365000C (zh) * | 2003-09-18 | 2008-01-30 | 雍智全 | Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用 |
-
2005
- 2005-04-06 CN CNB2005100570010A patent/CN1319978C/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101186620B (zh) * | 2007-10-19 | 2010-09-08 | 中国科学院广州化学研究所 | 一种含酚羟基的二苯乙烯类化合物的磷酸酯盐的制备方法 |
CN101220054B (zh) * | 2008-01-29 | 2011-05-25 | 成都恒基医药科技有限公司 | 康普瑞汀a-4磷酸酯二钠盐的制备方法 |
CN101891772A (zh) * | 2010-07-16 | 2010-11-24 | 广东肇庆星湖生物科技股份有限公司 | 一种5’-核苷酸二钠的制备方法 |
CN101891772B (zh) * | 2010-07-16 | 2012-11-28 | 广东肇庆星湖生物科技股份有限公司 | 一种5’-核苷酸二钠的制备方法 |
CN102731565A (zh) * | 2011-04-07 | 2012-10-17 | 复旦大学 | 一种二苯乙烯类化合物的水溶性衍生物及其制备方法和用途 |
CN106146548A (zh) * | 2015-04-17 | 2016-11-23 | 中山大学 | 一种芳氧基磷酸酯单钠盐的制备及应用 |
CN106146548B (zh) * | 2015-04-17 | 2020-12-29 | 中山大学 | 一种芳氧基磷酸酯单钠盐的制备及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1319978C (zh) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI449707B (zh) | 新穎磷系雙酚及其衍生物之製造方法 | |
EP2078005B1 (en) | Process for preparing nebivolol | |
CN1319978C (zh) | 康布瑞汀化合物的制备方法 | |
CN101955481A (zh) | 一种盐酸缬更昔洛韦的制备方法 | |
JP5744738B2 (ja) | ネビボロールの調製方法 | |
CN113896674B (zh) | 一种阿普斯特的合成方法 | |
CN113856762A (zh) | 高聚Salen钴催化剂和制备方法及应用 | |
BG63542B1 (bg) | Методи и междинни съединения за получаване на заместени хроманолови производни | |
CN112300072A (zh) | 5-碘异喹啉类化合物的高收率合成方法 | |
CN114394884B (zh) | 一种烯丙基苯酚类化合物的制备方法 | |
CN114315679A (zh) | 一种乌帕替尼手性中间体的制备方法 | |
KR101134021B1 (ko) | 새로운 중간체를 이용하는 피타바스타틴 헤미칼슘의 신규한 제조방법 | |
CN109180725B (zh) | 一种炔基磷酸酯的制备方法 | |
CN112851619B (zh) | 一种含硒异色满化合物的合成方法 | |
CN114213249B (zh) | 一种度鲁特韦中间体的合成方法 | |
CN116120163B (zh) | 一种贝派地酸的合成方法及其中间体 | |
CN112794837B (zh) | 一种异色满化合物的合成方法 | |
CN113816855B (zh) | 合成手性烯丙基羧酸酯的方法 | |
KR101339648B1 (ko) | 신규한 아토바스타틴 중간체 및 이를 이용한 아토바스타틴의 제조 방법 | |
CN110194760B (zh) | 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法 | |
KR101061602B1 (ko) | 난연성 포스파펜안트렌 화합물 및 이의 제조방법 | |
KR20100009664A (ko) | 트란스 선택적 Wittig-Horner 반응을 이용한Piceatannol의 개선된 합성법 | |
JP2011046661A (ja) | 4置換不斉炭素を有するα−アミノリン酸化合物の製造方法 | |
CN100546973C (zh) | 3-(n-甲基-n-戊氨基)丙酸盐酸盐的制备方法 | |
CN116947922A (zh) | 一种匹伐他汀中间体的合成工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SOUTHWEST SYNTHETIC PHARMACEUTICAL CORP., LTD., PK Free format text: FORMER OWNER: SOUTHWEST SYNTHETIC PHARMACEUTICAL CORP. LTD. Effective date: 20110714 Owner name: PKU INTERNATIONAL HEALTHCARE GROUP CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 401147 NO. 34, HONGJIN ROAD, LONGXI TOWN, YUBEI DISTRICT, CHONGQING CITY TO: 401121 19/F, TOWER B, FORTUNE BUILDING, NO. 9, HONGHU EAST ROAD, YUBEI DISTRICT, CHONGQING CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110714 Address after: 19, building 9, building B, Fortune Tower, No. 401121, Honghu East Road, Chongqing, Yubei District Co-patentee after: Pku Healthcare Industry Group Co.,Ltd. Patentee after: SOUTHWEST SYNTHETIC PHARMACEUTICAL Corp.,Ltd. Address before: 401147 Chongqing city Yubei District Longxi Road No. 34 red Patentee before: Southwest Synthetic Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: PEKING UNIVERSITY HEALTHCARE CO., LTD. Free format text: FORMER NAME: PKUCARE SOUTHWEST SYNTHETIC PHARMACEUTICALS CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 19, building 9, building B, Fortune Tower, No. 401121, Honghu East Road, Chongqing, Yubei District Patentee after: PKU HEALTHCARE Corp.,Ltd. Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 19, building 9, building B, Fortune Tower, No. 401121, Honghu East Road, Chongqing, Yubei District Patentee before: SOUTHWEST SYNTHETIC PHARMACEUTICAL Corp.,Ltd. Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230609 Address after: No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing 400722 Patentee after: PKU HEALTHCARE Corp.,Ltd. Patentee after: Peking University Medical Management Co.,Ltd. Address before: 401121 19th floor, block B, Fortune Building, 9 Honghu East Road, Yubei District, Chongqing Patentee before: PKU HEALTHCARE Corp.,Ltd. Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
TR01 | Transfer of patent right |